About us

Polbionica – innovation biotechnic company. We develop a 3D bionic pancreas and supply key products for the advancement of 3D bioprinting.

Polbionica is a spin-off from the Foundation of Research and Science Development, which bioprinted the world’s first bionic pancreas with full vasculature in March 2019. Polbionica holds expertise in bioprinting and type 1 diabetes (T1D), and has an extensive collaborative network of experts and Key Opinion Leaders.
Our mission is to introduce 3D bioprinting into clinical practice worldwide. Our vision is a fully functional bionic pancreas as a new gold standard T1D treatment. Our strategy is to bring to market the key building blocks for the bioprinting of a bionic organ: a novel bioreactor ReaserchLine and bioinks’s line TintaBionic and Printiss with unique physiological properties. Polbionica aims to fill the gap between organ shortage and transplantation needs.

The research team has benefited from a €6M STRATEGMED grant from the National Centre for Research and Development in Poland to develop the technology. Our achievements as pioneers of the niche of bionic pancreas received international media coverage. Our efforts were also acknowledged by numerous awards: Golden Leader of Health Care (category Innovative Ideas), Golden Scalpel award for the innovators in Polish Health Care, and “Poster of distinction” and “Best in Congress Poster” from the American Transplant Congress. Our Phase 1 SME instrument application received Seal of Excellence.

Polbionica Quality Management System – ISO 13485 Certification and Commitment to Medical Innovation – Quality Policy

A key element in achieving Polbionica’s ambitious goals is the implementation and continuous improvement of a Quality Management System compliant with the international ISO 13485 standard.

This system reflects our commitment to upholding the highest standards in meeting legal, regulatory, and other requirements related to our activities in the field of medical devices.
On March 13, 2025, following a rigorous audit, United Registrar of Systems (URS) awarded Polbionica a certificate confirming that our Quality Management System complies with the ISO 13485 standard.
This certification is a testament to our continuous dedication to ensuring the safety, effectiveness, and reliability of our products — building trust among customers, partners, and medical institutions.

Polbionica declares full adherence to the implemented Quality Policy, which forms the foundation of our operations.
This policy encompasses a rigorous approach to the design, manufacturing, and testing of bioprinted products, ensuring their highest quality and compliance with stakeholder expectations.

Thanks to ISO 13485 certification and the continuous improvement of our processes, Polbionica is strengthening its position as a leader in the field of 3D bioprinting, contributing to the advancement of cutting-edge medical technologies in both the Polish and international markets.

What makes us stand out

Innovation

We deal with an innovative field on a global scale.

Pursuing a goal

Our main motivation is the goal we want to achieve.

Experience and passion

Our team consists of experts who are passionate about their work.

Quality

The effects of our work are always of the highest quality.

Partnership

We focus on partnership relations with our clients.

Our team

Polbionica is an interdisciplinary, committed and open to challenges team.

Our team consists of doctors, medical consultants, biotechnologists, engineers and laboratory technicians, but also quality experts, business creators, specialists in… sales and administration. Together, we strive to improve the lives of patients with diabetes.